Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy

Objective Activin A, an inflammatory mediator implicated in cellular senescence-induced adipose tissue dysfunction and profibrotic kidney injury, may become a new target for the treatment of diabetic kidney disease (DKD) and chronic kidney diseases. We tested the hypothesis that human DKD-related injury leads to upregulation of activin A in blood and urine and in a human kidney cell model. We further hypothesized that circulating activin A parallels kidney injury markers in DKD. Research design and methods In two adult diabetes cohorts and controls (Minnesota, USA; Galway, Ireland), the relationships between plasma (or urine) activin A, estimated glomerular filtration rate (eGFR) and DKD injury biomarkers were tested with logistic regression and correlation coefficients. Activin A, inflammatory, epithelial-mesenchymal-transition (EMT) and senescence markers were assayed in human kidney (HK-2) cells incubated in high glucose plus transforming growth factor-β1 or albumin. Results Plasma activin A levels were elevated in diabetes (n=206) compared with controls (n=76; 418.1 vs 259.3 pg/mL; p<0.001) and correlated inversely with eGFR (rs=−0.61; p<0.001; diabetes). After eGFR adjustment, only albuminuria (OR 1.56, 95% CI 1.16 to 2.09) and tumor necrosis factor receptor-1 (OR 6.40, 95% CI 1.08 to 38.00) associated with the highest activin tertile. Albuminuria also related to urinary activin (rs=0.65; p<0.001). Following in vitro HK-2 injury, activin, inflammatory, EMT genes and supernatant activin levels were increased. Conclusions Circulating activin A is increased in human DKD and correlates with reduced kidney function and kidney injury markers. DKD-injured human renal tubule cells develop a profibrotic and inflammatory phenotype with activin A upregulation. These findings underscore the role of inflammation and provide a basis for further exploration of activin A as a diagnostic marker and therapeutic target in DKD.

[1]  Shahrukh K Hashmi,et al.  Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease , 2019, EBioMedicine.

[2]  Vasilis Ntranos,et al.  Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. , 2019, Cell metabolism.

[3]  J. Bonventre,et al.  Cellular Senescence in the Kidney. , 2019, Journal of the American Society of Nephrology : JASN.

[4]  M. Jensen,et al.  Targeting senescent cells alleviates obesity‐induced metabolic dysfunction , 2019, Aging cell.

[5]  Jennifer K. Sun,et al.  A Signature of Circulating Inflammatory Proteins and Development of End Stage Renal Disease in Diabetes , 2019, Nature Medicine.

[6]  M. Griffin,et al.  Defining reference intervals for a serum growth differentiation factor-15 (GDF-15) assay in a Caucasian population and its potential utility in diabetic kidney disease (DKD) , 2018, Clinical chemistry and laboratory medicine.

[7]  M. Jayakumar,et al.  Inflammation and nutritional status assessment by malnutrition inflammation score and its outcome in pre-dialysis chronic kidney disease patients. , 2019, Clinical nutrition.

[8]  L. Peng,et al.  Association between serum activin A and metabolic syndrome in older adults: Potential of activin A as a biomarker of cardiometabolic disease , 2018, Experimental Gerontology.

[9]  M. McCarthy,et al.  Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes , 2018, Diabetes Care.

[10]  D. Allison,et al.  Senolytics Improve Physical Function and Increase Lifespan in Old Age , 2018, Nature Medicine.

[11]  M. Morevati,et al.  Klotho and activin A in kidney injury: plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in the contralateral kidney. , 2018, American journal of physiology. Renal physiology.

[12]  K. Hiromura,et al.  Identification of Urinary Activin A as a Novel Biomarker Reflecting the Severity of Acute Kidney Injury , 2018, Scientific Reports.

[13]  R. Testa,et al.  Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages , 2017, Redox biology.

[14]  K. Hruska,et al.  The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. , 2018, Kidney international.

[15]  M. Griffin,et al.  Influence of Referral to a Combined Diabetology and Nephrology Clinic on Renal Functional Trends and Metabolic Parameters in Adults With Diabetic Kidney Disease , 2017, Mayo Clinic proceedings. Innovations, quality & outcomes.

[16]  D. Power,et al.  NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy , 2017, Diabetes.

[17]  N. LeBrasseur,et al.  Targeting cellular senescence prevents age-related bone loss in mice , 2017, Nature Medicine.

[18]  L. Fried,et al.  Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease. , 2017, Journal of the American Society of Nephrology : JASN.

[19]  Lindsay A. Williams,et al.  Sav1 Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis , 2017, Molecular and Cellular Biology.

[20]  K. Hiromura,et al.  Involvement of infiltrating macrophage-derived activin A in the progression of renal damage in MRL-lpr mice. , 2017, American journal of physiology. Renal physiology.

[21]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[22]  K. Hruska,et al.  Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. , 2016, Kidney international.

[23]  L. Lerman,et al.  Challenges and opportunities for stem cell therapy in patients with chronic kidney disease. , 2016, Kidney international.

[24]  M. Breuning,et al.  Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[25]  M. Griffin,et al.  The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease , 2016, Current Diabetes Reports.

[26]  M. Jensen,et al.  Targeting senescent cells enhances adipogenesis and metabolic function in old age , 2015, eLife.

[27]  R. Kalluri,et al.  Epithelial to Mesenchymal Transition induces cell cycle arrest and parenchymal damage in renal fibrosis , 2015, Nature Medicine.

[28]  Li-Rong Lin,et al.  Impact of ER stress-regulated ATF4/p16 signaling on the premature senescence of renal tubular epithelial cells in diabetic nephropathy. , 2015, American journal of physiology. Cell physiology.

[29]  K. Hiromura,et al.  Follistatin, an Activin Antagonist, Ameliorates Renal Interstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction , 2014, BioMed research international.

[30]  Yijun Yang,et al.  Multiple‐dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA‐IgG1), a novel erythropoietic agent, in healthy postmenopausal women , 2013, Journal of clinical pharmacology.

[31]  A. Levin,et al.  Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[32]  K. Nair,et al.  Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. , 2012, Mayo Clinic proceedings.

[33]  T. Mayadas,et al.  Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.

[34]  R. Blantz,et al.  Transition of kidney tubule cells to a senescent phenotype in early experimental diabetes. , 2010, American journal of physiology. Cell physiology.

[35]  Masayuki Orimo,et al.  A crucial role for adipose tissue p53 in the regulation of insulin resistance , 2009, Nature Medicine.

[36]  K. Tsuchida,et al.  Activin signaling as an emerging target for therapeutic interventions , 2009, Cell Communication and Signaling.

[37]  Gang Liu,et al.  Effect of activin A on tubulointerstitial fibrosis in diabetic nephropathy , 2009, Nephrology.

[38]  G. Deferrari,et al.  Accelerated senescence in the kidneys of patients with type 2 diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[39]  María Teresa Croda-Todd,et al.  Adult cystatin C reference intervals determined by nephelometric immunoassay. , 2007, Clinical biochemistry.

[40]  Tom Greene,et al.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. , 2007, Clinical chemistry.

[41]  K. Budde,et al.  Glomerular activin A overexpression is linked to fibrosis in anti-Thy1 glomerulonephritis. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[42]  A. Melk,et al.  Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. , 2004, Kidney international.

[43]  Y. Nojima,et al.  Activin A is a potent activator of renal interstitial fibroblasts. , 2004, Journal of the American Society of Nephrology : JASN.

[44]  P. Kimmel,et al.  Longitudinal and cross-sectional effects of C-reactive protein, equilibrated normalized protein catabolic rate, and serum bicarbonate on creatinine and albumin levels in dialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  Shin Yamashita,et al.  Activin a produced by ureteric bud is a differentiation factor for metanephric mesenchyme. , 2003, Journal of the American Society of Nephrology : JASN.

[46]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[47]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  T. Naruse,et al.  Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats. , 2001, Journal of the American Society of Nephrology : JASN.

[50]  Y. Sakamoto,et al.  Serum immunoreactive activin A levels in normal subjects and patients with various diseases. , 1996, The Journal of clinical endocrinology and metabolism.

[51]  R. Jaenisch,et al.  Functional analysis of activins during mammalian development , 1995, Nature.

[52]  R. Zager,et al.  HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. , 1994, Kidney international.

[53]  K. Iseki,et al.  Serum albumin is a strong predictor of death in chronic dialysis patients. , 1993, Kidney international.